Acceptance of Oclacitinib Maleate (Apoquel®) Chewable Tablets In Client-Owned Dogs With Allergic And Atopic Dermatitis.

Abstract excerpt

<h4>Background: </h4> The oral acceptance of oclacitinib maleate (Apoquel®) chewable tablets administered twice daily for 7 days at the labeled dose range of 0.4-0.6 mg/kg was evaluated in 121 dogs treated at ten general practice veterinary clinics in the United States. <h4>Results: </h4>: Dogs that were enrolled in the study ranged were client-owned, from 1 to 14 years of age, weighed 3.7 to 60.7 kg, and required...

Topics

Open a Topic to create a Post that cites this publication.

• Administration, Intravenous
• Area Under Curve
• ATP Binding Cassette Transporter, Subfamily B, Member 1
• Dogs
• Dopamine Antagonists
• Dose-Response Relationship, Drug
• Genotype
• Mutation

Identifiers and source

Literature Corpus work

95aa8321-9b7a-5ed9-970c-e7e6a5a50ff5

DOI

10.21203/rs.3.rs-1174474/v1